Tag: Delix Therapeutics - Psychedelic Alpha

Read more about the article Delix Therapeutics Announces Completion of 1st Cohort Dosing, Dose Escalation Approval in Phase I Trial for Novel Compound DLX-001

Delix Therapeutics Announces Completion of 1st Cohort Dosing, Dose Escalation Approval in Phase I Trial for Novel Compound DLX-001

Post published:June 20, 2023
Post category:Press Release

Read more about the article Delix Therapeutics Appoints Aaron Koenig, MD as Chief Medical Officer

Delix Therapeutics Appoints Aaron Koenig, MD as Chief Medical Officer

Post published:June 12, 2023
Post category:Press Release

Read more about the article Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001

Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001

Post published:May 9, 2023
Post category:Press Release

Read more about the article Pioneering Delix Therapeutics Study Published in ‘Science’ Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity

Pioneering Delix Therapeutics Study Published in ‘Science’ Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity

Post published:February 16, 2023
Post category:Press Release

Read more about the article Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability

Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability

Post published:February 14, 2023
Post category:Press Release

Read more about the article Delix Therapeutics Expands World-Class Team with First Head of R&D

Delix Therapeutics Expands World-Class Team with First Head of R&D

Post published:September 23, 2022
Post category:Press Release

Read more about the article Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up

Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up

Post published:September 13, 2022
Post category:Press Release

Read more about the article Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank

Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank

Post published:January 10, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.